Recent News
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
...
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
...
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
...
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
...